Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — Shareholder Meeting (August 2017)
17 slides from Aft Pharmaceuticals's shareholder meeting presentation, Aug 4, 2017
Slide 1: AFT Pharmaceuticals Annual Meeting
For personal use only AFT PHARMACEUTICALS Annual Meeting 4 August 2017
Slide 2: Important Notice
For personal use only IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New
Slide 3: CEO Presentation
For personal use only CEO Presentation
Slide 4: Summary of AFT Business
SUMMARY OF AFT BUSINESS Established Business [1997] and growing AU & NZ Significant further potential growth in AU • - Grow newly launched and existing OTCs For personal use only • - Grow Maxigesic from Codeine switch Development of Key Innovative Products with Global Potential The most significant
Slide 5: Current Highlights
CURRENT HIGHLIGHTS Countries that Maxigesic is now licensed in For personal use only 124 9 Countries that Maxigesic is launched and sold in Further launch orders being processed now $70.8m Total income for FY2017* $16.0m Available cash as at 31 March 2017 Development goals are being achieved Progres
Slide 6: Financial Performance – Revenue Growth
FINANCIAL PERFORMANCE – REVENUE GROWTH Operating revenue, FY2000 – FY2017 80 For personal use only 70 Operating revenue (NZ$m) 10 year C AGR: 15% 60 50 40 30 20 10 - FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY2016 Operating revenue by region FY2017 Operating revenue by region
Slide 7: Financial Performance – Revenue by Region and Channel
FINANCIAL PERFORMANCE – REVENUE BY REGION AND CHANNEL Operating revenue by region, FY2015 – FY2017 For personal use only NZ$000's year ended March 2017 2015 % of total 2016 % of total 2017 % of total Australia 26,324 46.8% 31,224 48.8% 37,063 53.6% YoY growth 18.6% 18.7% New Zealand 29,398 52.3% 31,
Slide 8: Financial Performance – Summary P&L
FINANCIAL PERFORMANCE – SUMMARY P&L NZ$'000's year ended 31 March 2017 % of 2016 % of revenue revenue For personal use only Revenue 69,205 64,014 Cost of Sales (43,207) 62.4% (40,435) 63.2% Gross Profit 25,998 37.6% 23,579 36.8% Other Income 2,659 3.8% 2,295 3.6% Selling and distribution expenses (2
Slide 9: Financial Performance – Summary Balance Sheet
FINANCIAL PERFORMANCE – SUMMARY Balance Sheet NZ$'000's year ended 31 March 2017 2016 ASSETS Current Assets Inventories 18,718 16,499 For personal use only Trade and other receivables 19,362 17,475 Cash and cash equivalents 15,980 28,055 Current income tax asset - 26 Total current assets 54,060 62,0
Slide 10: Financial Performance – Summary Cashflow
For personal use only FINANCIAL PERFORMANCE – SUMMARY Cashflow NZ$'000's year ended 31 March 2017 2016 Net cash used in operating activities (19,062) (13,942) Net cash used in investing activities (1,598) (1,181) Net cash generated from financing activities 9,042 36,705 Net increase in cash (11,618)
Slide 11: Maxigesic Update
MAXIGESIC UPDATE Nordics – launch pending Eastern Europe and Balkans – launches pending BE/LX & FR– launches pending Italy – successful launch and UK – launched sales increasing significantly For personal use only IE – launch pending Kuwait and Iraq launc pending UAE – sales doubled in second year o
Slide 12: Maxigesic Tablet Sales Progress to Date
For personal use only MAXIGESIC TABLET SALES PROGRESS TO DATE 80,000,000 70,000,000 60,000,000 50,000,000 40,000,000 30,000,000 20,000,000 10,000,000 - FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 All Ma rke ts Maxigesic Tablets Sold [Mill] Per Year Note: Only this FY18 year Maxigesic will become AFT’s b
Slide 13: Example of Maxigesic Licensee Progress to Date
EXAMPLE OF MAXIGESIC LICENCEE PROGRESS TO DATE – tablet sales per month Maxigesic S ales (Tablets) For personal use only 900,000 800,000 700,000 600,000 Tablets per Month 500,000 400,000 300,000 200,000 100,000 - Ma xig e s ic Ta ble ts Lin e a r (Ma xig e s ic Ta b le ts ) Annual Meeting 12 4 Augus
Slide 14: Maxigesic: Future Growth Strategy
MAXIGESIC: Future growth strategy Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase the number of countries to 124. For personal use only Some additional larger countries to be added – North America larger EU market France [2nd largest m
Slide 15: Maxigesic: Australian Growth Strategy
MAXIGESIC: Australian growth strategy • Prior to the re-scheduling of codeine-based analgesics, our growth estimates were for For personal use only sales increasing in Australia from 13 to 26 million tablets in FY2018. • Codeine switch confirmed for 1st February 2018. • Codeine tablet market is 750
Slide 16: NasoSURF Nebuliser: Future Growth Strategy
NASOSURF NEBULISER: Future growth strategy A handheld ultrasonic nasal mesh nebuliser for the Product intranasal delivery of medication and treatment of description chronic sinusitis For personal use only The NasoSURF Nebuliser has desirable features over currently marketed nebulisers, which are not
Slide 17: Summary of Medium Term Plans
SUMMARY OF MEDIUM TERM PLANS Phased launches of Maxigesic in over 110 countries including North America For personal use only Add additional Maxigesic dose forms to the initial launches to extend sales Further licensing agreements for Maxigesic and Maxigesic IV in larger markets including North Amer
AFT Pharmaceuticals — Shareholder Meeting (August 2017) on 6ix